Jacksonville, FL
Marriott Jacksonville Downtown
March 6, 2027
TBD CE/CME/CPE and ABPath MOC

Advancing Precision Cancer Care Through Multidisciplinary Collaboration
Jacksonville, FL
March 6, 2027

Advancing the Diagnostic-to-Treatment Continuum in Hematologic Malignancies – Jacksonville

Jacksonville brings together leading experts in hematologic oncology, hematopathology, molecular diagnostics, and translational science to explore the rapidly evolving care of patients with hematologic malignancies.

Chaired by Julio Chavez, MD, of Mayo Clinic in Jacksonville, Florida, and Omar Castaneda Puglianini, MD, of Moffitt Cancer Center and the University of South Florida, the conference will examine how advances in disease biology, molecular diagnostics, and emerging therapies are reshaping the diagnosis and treatment of blood cancers.

Through expert-led presentations, multidisciplinary discussion, and clinically relevant case-based education, the program will highlight evolving approaches across leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and other hematologic malignancies.

Participants will gain practical insights into molecular and genomic profiling, biomarker testing, measurable residual disease (MRD), evolving disease classification, targeted therapies, immunotherapy, cellular therapy, and emerging treatment strategies – with an emphasis on translating diagnostic and molecular findings into more informed, individualized treatment decisions.

By bringing together the specialists responsible for diagnosis, molecular characterization, and treatment, the Jacksonville conference connects the laboratory and the clinic across the full diagnostic-to-treatment continuum in hematologic cancer care.

Agenda

Saturday – March 6, 2027
7:30 AM	Registration & Check-in
8:00 AM	Welcome and Introductions
8:10 – 9:40 AM	Session I: Advances in Leukemia
9:40 – 9:55 AM	Breakfast & Exhibits
9:55 – 10:40 AM	Non-CME Session
10:40 – 12:10 PM	Session II: Advances in Multiple Myeloma
12:10 – 12:40 PM	Session III: Keynote – Advances in Hematology
12:40 – 12:55 PM	Lunch & Exhibits
12:55 – 1:40 PM	Non-CME Session
1:40 – 1:50 PM	Break & Exhibits
1:50 – 3:20 PM	Session IV: Lymphoma & Myelodysplastic Syndromes: Evolving Approaches
3:20 – 3:35 PM	Break & Exhibits
3:35 – 5:05 PM	Session V: Myeloproliferative Neoplasms & Future Directions in Hematologic Malignancies
5:05 PM	Adjourn

Learning Objectives

Evaluate current and emerging diagnostic, molecular, and therapeutic approaches across hematologic malignancies, including leukemia, multiple myeloma, lymphoma, myelodysplastic syndromes, and myeloproliferative neoplasms.
Integrate disease biology, biomarker and molecular findings, and evolving clinical evidence into individualized treatment selection and sequencing for patients with hematologic malignancies.

Accreditation Information | TBD CE/CME/CPE and ABPath MOC Credits

Speakers

CO-CHAIR
Omar Castaneda Puglianini, MD
Medical Director, SONIC Service
Moffitt Cancer Center & Research Institute
View Profile
Associate Member
Tenured Member
Medical Director SONIC Service
Blood & Marrow Transplant & Cellular Immunotherapy
Pentecost Family Myeloma Research Center
H. Lee Moffitt Cancer Center & Research Institute
Associate Professor of Medicine
University of South Florida
Dr. Castaneda Puglianini is an Associate Member in the Department of Blood and Marrow Transplant and Cellular Immunotherapy (BMT-CI) and serves as Medical Director of the Specialized Oncology Non-Cellular Immunotherapy Comprehensive Care Service (SONIC) at Moffitt Cancer Center and Research Institute. He is also an Associate Professor in the Department of Oncologic Sciences at the University of South Florida.
Dr. Castaneda Puglianini earned his medical degree from Universidad Peruana Cayetano Heredia in Lima, Peru, followed by residency training in Internal Medicine at Albert Einstein College of Medicine in New York. He completed fellowship training in Hematology and Oncology at Virginia Commonwealth University (VCU) Massey Comprehensive Cancer Center and subsequently completed a fellowship in Blood and Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center.
Prior to joining Moffitt, he served as Director of the CAR T-Cell Therapy Program within the Division of Hematology, Oncology, and Palliative Care at VCU Massey Comprehensive Cancer Center. His clinical practice focuses on the management of hematologic malignancies, with particular expertise in plasma cell neoplasms and the integration of autologous and allogeneic hematopoietic stem cell transplantation, cellular therapies, and non-cellular immunotherapeutic approaches.
His academic and research interests center on advancing the treatment of multiple myeloma and other plasma cell disorders. His work focuses on identifying prognostic and predictive factors associated with disease progression, defining the role of minimal residual disease (MRD) in clinical decision-making, and developing and evaluating novel cellular and non-cellular immunotherapeutic strategies through clinical trials. His overarching goal is to advance personalized, evidence-based approaches that improve outcomes for patients with multiple myeloma.
CO-CHAIR
Julio Chavez, MD
Senior Associate Consultant, Division of Hematology and Oncology
Mayo Clinic, Florida
View Profile
Senior Associate Consultant, Division of Hematology/Oncology
Mayo Clinic, Florida
Dr. Julio Chavez is a Senior Associate Consultant in the Division of Hematology/Oncology at Mayo Clinic in Jacksonville, Florida, where he serves as the lymphoma lead and a principal investigator in clinical and translational research. He is an expert in the management and investigation of lymphoid malignancies, with a particular focus on aggressive B-cell lymphomas, targeted therapies, immunotherapies, and cellular therapies including CAR-T cell approaches.
Dr. Chavez earned his medical degree from Universidad Peruana Cayetano Heredia in Lima, Peru, and completed residency training in internal medicine in the United States, followed by advanced fellowship training in hematology and medical oncology. He is board-certified in Internal Medicine and Medical Oncology and has dedicated his career to improving outcomes for patients with complex lymphoid malignancies through both innovative clinical care and research.
As a clinical investigator, Dr. Chavez has served as principal investigator on multiple trials evaluating targeted agents, immunotherapy combinations, and novel cellular therapies, contributing to studies that have shaped FDA-approved treatment paradigms. His work has been published in high-impact journals including Journal of Clinical Oncology, Blood, and New England Journal of Medicine, and he is a frequent presenter at major national and international conferences such as the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO).
Dr. Chavez’s clinical and research program emphasizes translational science and individualized patient care, bridging advances in lymphoma biology with practical therapeutic strategies to expand and optimize options for patients across the disease spectrum.